Phase I study of ceritinib (LDK378) in Japanese patients with advanced, anaplastic lymphoma kinase-rearranged non-small-cell lung cancer or other tumors

Journal of Thoracic Oncology

Volumn 10, Issue 7, 2015, Pages 1058-1066

  Nishio, Makoto ^a   Murakami, Haruyasu ^b   Horiike, Atsushi ^a   Takahashi, Toshiaki ^b   Hirai, Fumihiko ^c   Suenaga, Naoko ^d   Tajima, Takeshi ^d   Tokushige, Kota ^d   Ishii, Masami ^d   Boral, Anthony ^e   Robson, Matthew ^f   Seto, Takashi ^c  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

^d NOVARTIS PHARMA K K   (Japan)

^e NOVARTIS PHARMA AG   (Switzerland)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Alectinib; ALK rearranged; Ceritinib; non small cell lung cancer

Indexed keywords

2 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 4 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO] 1,3,5 TRIAZINE; ALANINE AMINOTRANSFERASE; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ASPARTATE AMINOTRANSFERASE; CERITINIB; CREATININE; CRIZOTINIB; TRIACYLGLYCEROL LIPASE; ANTIFREEZE PROTEIN; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; SULFONE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHOLANGITIS; CLINICAL ARTICLE; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; HYPERURICEMIA; IMMUNOHISTOCHEMISTRY; JAPANESE (PEOPLE); LIVER INJURY; MACULOPAPULAR RASH; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; STOMATITIS; TREATMENT RESPONSE; VOMITING; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; ENZYMOLOGY; GENE REARRANGEMENT; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; ANTIFREEZE PROTEINS, TYPE I; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONES;

EID: 84942908731     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000566     Document Type: Article

References (26)

1. Morris SW, Kirstein MN, Valentine MB, Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994 263 1281 1284
2. Barreca A, Lasorsa E, Riera L, European T-Cell Lymphoma Study Group Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol 2011 47 R11 R23
3. Soda M, Choi YL, Enomoto M, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007 448 561 566
4. Rodig SJ, Mino-Kenudson M, Dacic S, Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009 15 5216 5223
5. Paik JH, Choe G, Kim H, Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011 6 466 472
6. Shaw AT, Yeap BY, Mino-Kenudson M, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009 27 4247 4253
7. Camidge DR, Bang YJ, Kwak EL, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012 13 1011 1019
8. Kim D, Ahn M, Yang P, Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Ann Oncol 2012 23
9. Shaw AT, Kim DW, Nakagawa K, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013 368 2385 2394
10. Katayama R, Shaw AT, Khan TM, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012 4 120ra17
11. Doebele RC, Pilling AB, Aisner DL, Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012 18 1472 1482
12. Choi CM., Overview of ALK and ROS1 rearranged lung cancer. Tuberc Respir Dis (Seoul) 2013 75 236 237
13. Sasaki T, Okuda K, Zheng W, The neuroblastoma-Associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-Translocated cancers. Cancer Res 2010 70 10038 10043
14. Sakamoto H, Tsukaguchi T, Hiroshima S, CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011 19 679 690
15. Seto T, Kiura K, Nishio M, CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-Arm, open-label, phase 1-2 study. Lancet Oncol 2013 14 590 598
16. Gadgeel SM, Gandhi L, Riely GJ, Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase study. Lancet Oncol 2014 15 1119 1128
17. Marsilje TH, Pei W, Chen B, Synthesis, structure-Activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 2013 56 5675 5690
18. Friboulet L, Li N, Katayama R, The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014 4 662 673
19. Shaw AT, Kim DW, Mehra R, Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014 370 1189 1197
20. Felip E, Kim D, Mehra R, Efficacy and safety of ceritinib in patients with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): an update of ASCEND-1. Poster Presented at ESMO 2014. Abstr # 1295P.
21. Katayama R, Friboulet L, Koike S, Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 2014
22. Neuenschwander B, Branson M, Gsponer T., Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 2008 27 2420 2439
23. Tan DSW, Shaw AT, Mehra R, Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC-subgroup analysis of the ASCEND-1 trial. J Clin Oncol 2014 32 5s
24. Shaw AT, Engelman JA., ALK in lung cancer: past, present, and future. J Clin Oncol 2013 31 1105 1111
25. Gainor JF, Sherman CA, Willoughby K, Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 2015 10 232 236
26. Choi YL, Soda M, Yamashita Y, ALK Lung Cancer Study Group EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010 363 1734 1739